Just finished listening to the archived call. I must say that I'm impressed with the integrity of Stephen Hill. At one point in the call he was asked if the current Phase I study included any pancreatic cancer patients. He carefully explained that he thought it ill advised to answer that question in order to maintain the integrity of the science. Even though we can assume he'd like to see the price of ARQL higher and could have answered that question (being in a public forum) legitimately, he chose to stick to his ethics.
Maybe this attitude is more pervasive than my cynical mind believes, but I'm glad we have it in the CEO of ArQule.
Disclaimer: currently long (probably for the next few years)